Clinical Trials Browser

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Phase 1 Completed

5 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Phase 2 Completed

12 enrolled 8 charts

Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

148 enrolled

Lymphoid

Lymphoma, T-Cell

NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 1 Completed

22 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT00085527 2013-09-05

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Phase 2 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Phase 1/2 Unknown

40 enrolled

Plasma cell

Multiple Myeloma

NCT00299351 2006-03-06

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Phase 2 Unknown

8 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.